MENA Newswire News Desk: The U.S. Food and Drug Administration (FDA) has approved Cobenfy, a new medication for the treatment of schizophrenia, marking the first major advance in this area in more than three decades. Cobenfy, developed by Bristol Myers Squibb, is a twice-daily oral medication that combines two drugs, xanomeline and trospium chloride, offering a new therapeutic option for managing schizophrenia symptoms like hallucinations, delusions, and disorganized thinking.
The FDA’s approval of Cobenfy offers fresh hope for millions of people living with schizophrenia, a severe mental health disorder that affects approximately 24 million people globally. According to Dr. Tiffany Farchione, Director of the Division of Psychiatry at the FDA’s Center for Drug Evaluation and Research, the approval breaks new ground in the treatment of this condition. “This is the first new approach to treating schizophrenia in decades, offering a valuable alternative to the antipsychotic medications that have been standard for so long,” she said.
Most existing schizophrenia treatments focus on altering dopamine levels in the brain, a neurotransmitter linked to mood and behavior. Cobenfy, however, targets acetylcholine receptors, a different pathway in the brain that influences memory, learning, and attention. This novel mechanism of action is particularly important for patients who experience side effects such as weight gain, drowsiness, or movement disorders from traditional antipsychotics.
In clinical trials, Cobenfy demonstrated significant effectiveness in reducing schizophrenia symptoms, with only 6% of patients discontinuing the drug due to side effects, compared to 20-30% with older medications. Dr. Samit Hirawat, Chief Medical Officer at Bristol Myers Squibb, hailed the results as a major improvement over previous treatment options.
Common side effects of Cobenfy include nausea, constipation, and increased heart rate, according to the FDA’s approval notice. However, these side effects were notably less severe than those caused by earlier medications. Dr. Leslie Citrome, a professor of psychiatry at New York Medical College, emphasized that the drug could benefit patients who cannot tolerate the side effects of current treatments.
Schizophrenia is a lifelong mental illness that typically begins in late adolescence or early adulthood and is characterized by distorted thinking, behavior, and emotions. It often leads to significant challenges in daily functioning, impacting work and relationships. The approval of Cobenfy could represent a breakthrough for patients who have struggled with available treatments for years. Cobenfy is expected to be available for prescription by the end of October, according to Adam Lenkowsky, Executive Vice President at Bristol Myers Squibb. Ongoing studies are also exploring its potential for treating other conditions, including Alzheimer’s disease and bipolar disorder.